Endonovo Launches Telehealth Initiative
Endonovo Therapeutics (OTCQB: ENDV) launched a telehealth initiative aimed at providing education and access to non-opioid pain management solutions. This platform will facilitate the distribution of their FDA-cleared SofPulse® device, which reduces the need for opioids in treating pain. With a growing shortage of healthcare professionals and rising demand for alternative pain management options, Endonovo seeks to educate communities about non-pharmacological treatments. The U.S. telehealth market is projected to grow at a CAGR of 44.4% from 2022 to 2028, highlighting significant market potential.
- Launch of telehealth platform to provide non-opioid pain management solutions.
- SofPulse® device is FDA cleared and effective in reducing pain and inflammation.
- Increased focus on education about non-pharmacological treatments.
- None.
Expands Patient Education, Access to Non-Opioid Options for Pain Management
Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the launching of a new initiative to utilize its telehealth platform to educate and provide prescription and “over the counter” non-opioid pain reduction options.
The Endonovo Telehealth platform will provide alternative pain management options through its direct-to-consumer sales of prescription and non-prescription uses of their SofPulse® Pulsed Electro Magnetic Frequency (PEMF) medical device proven to reduce opioid use.
Shortage of Physicians
“There is a massive and acute shortage of primary care physicians and other healthcare specialists prompting the need for patient information and product distribution systems which only a telehealth platform can provide,” according to Endonovo President and Chief Commercial Officer Ira Weisberg.
Weisberg will head company development and implementation of strategic approaches for non-opioid pain management initiatives based on latest advances in telehealth services and related technologies.
Need for Pain Management Options
Grandviewresearch.com reports: “The U.S. telehealth market is expected to expand at a compound annual growth rate (CAGR) of
Weisberg continued: “Our market research, along with our medical partners, clearly shows that patients are actively seeking non-pharmacological pain management options for treating their acute and chronic pain conditions.
“Our initiative is targeted to utilize the latest medical market research and planning, development of a robust telehealth platform and identifying and employing a leading telehealth partners that has expertise in HIPAA compliance and a proven ability to promote the initiative effectively to potential users. Our telehealth initiative will help individuals and communities understand the risks of opioid use and alternative treatments available so they are able to make informed decisions about their treatment options.”
Weisberg also pointed out: “For the moment, “SofPulse® is our first product to be discussed on our platform. It is FDA cleared for the reduction of pain and edema (Inflammation) post-operatively and has been shown to reduce both pain and inflammation in multiple clinical applications and studies.
“The SofPulse® medical device has shown to be an effective holistic drug-free alternative to opioids for pain management which can help patients significantly reduce opioid use when dealing with acute and chronic pain conditions.”
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics is now structured into two divisions: Legacy – a commercial-stage developer primarily of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives with many of its products marketed under the SofPulse® brand name; and its Build Up Strategy – acquiring complementary specialty service providers in the construction industry.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Steve Barnes
(800) 701-1223 Ext. 108
sbarnes@endonovo.com
www.endonovo.com
Media Contact:
Gregory A. McAndrews
Greg McAndrews & Associates
(310) 804-7037
greg@gregmcandrews.com
FAQ
What is the latest initiative from Endonovo Therapeutics?
How does the SofPulse<sup>®</sup> device relate to opioid use?
What is the expected growth rate of the U.S. telehealth market?
What challenges is the telehealth initiative addressing?
